ArticlePloS one2013
Corneal endothelial expansion promoted by human bone marrow mesenchymal stem cell-derived conditioned medium.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 97 citations in OpenAlex.
- Delayed limbal mesenchymal stem cell secretome therapy attenuates NF-κB, IL-8, and MMP-9 expression following phacoemulsification-induced corneal endothelial damage.BMC ophthalmology · 2026Article
- Decreased Corneal Endothelial Cell Apoptosis Due to U/S Power Injury With Limbal Mesenchymal Stem Cell Secretome Therapy.Stem cells international · 2026Article
- Strategies for Differentiation of Corneal Endothelial Cells From Stem Cells: Current Advances and Challenges.Stem cells international · 2026Review
- Bioengineering Strategies for Corneal Endothelial Cell Injection Therapy: Advances, Challenges, and Clinical Translation.Bioengineering (Basel, Switzerland) · 2025Review
- The hiPSC-derived corneal endothelial progenitor-like cell recovers the rabbit model of corneal endothelial dystrophy.Journal of advanced research · 2025Article
- Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025Review
- Posterior Limbal Mesenchymal Stromal Cells Promote Proliferation and Stemness of Transition Zone Cells: A Novel Insight Into Corneal Endothelial Rejuvenation.Investigative ophthalmology & visual science · 2025Article
- Molecular and Cellular Mechanisms of the Therapeutic Effect of Mesenchymal Stem Cells and Extracellular Vesicles in Corneal Regeneration.International journal of molecular sciences · 2024Review
- Mesenchymal Stem Cells and Exosomes: A Novel Therapeutic Approach for Corneal Diseases.International journal of molecular sciences · 2023Review
- Anti-apoptotic and autophagic effect: Using conditioned medium from human bone marrow mesenchymal stem cells to treat human trabecular meshwork cells.Regenerative therapy · 2023Article
- Effects of Y-27632, a Rho-associated Kinase Inhibitor, on Human Corneal Endothelial Cells Cultured by Isolating Human Corneal Endothelial Progenitor Cells.Korean journal of ophthalmology : KJO · 2023Article
- Fluctuations in Corneal Endothelial LAP2 Expression Levels Correlate with Passage Dependent Declines in Their Cell Proliferative Activity.International journal of molecular sciences · 2022Article
- Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos.Stem cell reviews and reports · 2022Review
- Regenerative therapy for the Cornea.Progress in retinal and eye research · 2022Review
- Isolation efficiency of collagenase and EDTA for the culture of corneal endothelial cells.Molecular vision · 2022Article
- Corneal endothelial cell therapy: feasibility of cell culture from corneas stored in organ culture.Cell and tissue banking · 2021Article
- Article
- Decreased Inhibition of Proliferation and Induction of Apoptosis in Breast Cancer Cell Lines (T47D and MCF7) from Treatment with Conditioned Medium Derived from Hypoxia-Treated Wharton's Jelly MSCs Compared with Normoxia-Treated MSCs.International journal of hematology-oncology and stem cell research · 2021Article
- Experimental design of a culture approach for corneal endothelial cells of New Zealand white rabbit.Heliyon · 2020Article
- Bioengineering Approaches for Corneal Regenerative Medicine.Tissue engineering and regenerative medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Healthy corneal endothelium is essential for maintaining corneal clarity, as the damage of corneal endothelial cells and loss of cell count causes severe visual impairment. Corneal transplantation is currently the only therapy for severe corneal disorders. The greatly limited proliferative ability of human corneal endothelial cells (HCECs), even in vitro, has challenged researchers to establish efficient techniques for the cultivating HCECs, a pivotal issue for clinical applications. The aim of this study was to evaluate conditioned medium (CM) obtained from human bone marrow-derived mesenchymal stem cells (MSCs) (MSC-CM) for use as a consistent expansion protocol of HCECs. When HCECs were maintained in the presence of MSC-CM, cell morphology assumed a hexagonal shape similar to corneal endothelial cells in vivo, as opposed to the irregular cell shape observed in control cultures in the absence of MSC-CM. They also maintained the functional protein phenotypes; ZO-1 and Na(+)/K(+)-ATPase were localized at the intercellular adherent junctions and pump proteins of corneal endothelium were accordingly expressed. In comparison to the proliferative potential observed in the control cultures, HCECs maintained in MSC-CM were found to have more than twice as many Ki67-positive cells and a greatly increased incorporation of BrdU into DNA. MSC-CM further facilitated the cell migration of HCECs. Lastly, the mechanism of cell proliferation mediated by MSC-CM was investigated, and phosphorylation of Akt and ERK1/2 was observed in HCECs after exposure to MSC-CM. The inhibitor to PI 3-kinase maintained the level of p27(Kip1) for up to 24 hours and greatly blocked the expression of cyclin D1 and D3 during the early G1 phase, leading to the reduction of cell density. These findings indicate that MSC-CM not only stimulates the proliferation of HCECs by regulating the G1 proteins of the cell cycle but also maintains the characteristic differentiated phenotypes necessary for the endothelial functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.